A detailed history of Guardian Wealth Advisors, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Guardian Wealth Advisors, LLC holds 4,252 shares of BMY stock, worth $239,047. This represents 0.03% of its overall portfolio holdings.

Number of Shares
4,252
Previous 5,829 27.05%
Holding current value
$239,047
Previous $242,000 9.09%
% of portfolio
0.03%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$39.66 - $51.75 $62,543 - $81,609
-1,577 Reduced 27.05%
4,252 $220,000
Q2 2024

Aug 14, 2024

SELL
$40.25 - $52.99 $48,662 - $64,064
-1,209 Reduced 17.18%
5,829 $242,000
Q1 2024

May 15, 2024

BUY
$47.98 - $54.4 $31,714 - $35,958
661 Added 10.37%
7,038 $381,000
Q4 2023

Feb 14, 2024

SELL
$48.48 - $57.85 $29,815 - $35,577
-615 Reduced 8.8%
6,377 $327,000
Q3 2023

Nov 14, 2023

SELL
$57.89 - $64.73 $40,465 - $45,246
-699 Reduced 9.09%
6,992 $405,000
Q2 2023

Aug 14, 2023

BUY
$63.71 - $70.74 $20,960 - $23,273
329 Added 4.47%
7,691 $491,000
Q1 2023

May 15, 2023

SELL
$65.71 - $74.53 $5,453 - $6,185
-83 Reduced 1.11%
7,362 $510,000
Q4 2022

Feb 14, 2023

SELL
$68.48 - $81.09 $1,164 - $1,378
-17 Reduced 0.23%
7,445 $535,000
Q3 2022

Nov 14, 2022

SELL
$0.13 - $76.84 $109 - $64,776
-843 Reduced 10.15%
7,462 $530,000
Q2 2022

Aug 15, 2022

BUY
$72.62 - $79.98 $69,352 - $76,380
955 Added 12.99%
8,305 $644,000
Q1 2022

May 16, 2022

BUY
$61.48 - $73.72 $7,992 - $9,583
130 Added 1.8%
7,350 $541,000
Q4 2021

May 16, 2022

BUY
$53.63 - $62.52 $387,208 - $451,394
7,220 New
7,220 $450,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $120B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Guardian Wealth Advisors, LLC Portfolio

Follow Guardian Wealth Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Guardian Wealth Advisors, LLC , based on Form 13F filings with the SEC.

News

Stay updated on Guardian Wealth Advisors, LLC with notifications on news.